NSCLC patients with high neoplastic ICAM-1 expression and serum soluble ICAM-1 levels show more aggressive lung cancer progression [4–6], suggesting a potential role of ICAM-1 in promoting NSCLC. Here, ICAM1 is linked to lung cancer.